NMPA Approves Zorifertinib Hydrochloride Tablets (Zerini) for First-Line Treatment of NSCLC with CNS Metastases

Recently, the National Medical Products Administration approved the marketing of Zorifertinib Hydrochloride Tablets (brand name: Zerene), a Class 1 innovative drug submitted by Alpha Biopharma. This medication is suitable for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases, providing a new treatment option for patients.

Source/ Website of the National Medical Products Administration

PD-1/VEGF Bispecific Antibody Boom! Primus Bio Acquired, Limin Partners with Merck. Who’s Next in the Big Deal?

Wave of M&A! Zhongsheng, Kangyuan, Dongbei Continuously Make Moves; Is Industry Integration Accelerating?

Innovative Medical Insurance Settlement Methods and Establishment of an Advance Payment System Break the Ice on Hospital Repayment Difficulties

In the first three quarters, Novo Nordisk's semaglutide exceeded $200 billion in sales! Lilly is closing in, will Keytruda's "top drug" status be at risk?

www.yyjjb.com.cn

Insight into Industry Trends

Long press to followPharmaceutical Economy News

"Pharmaceutical Economy Herald"

Academic Official Account

Focusing on the Frontiers of Oncology Academia

Press and hold to followImmunity Time

"Pharmaceutical Economy News"

Terminal Official Account

Record Major Events in the Pharmaceutical Terminal Industry

Long press to follow21st Century Pharmacy